Search results
Results from the WOW.Com Content Network
The drug is designed by a team of Novo Nordisk researchers. [1] NNC2215 can sense the glucose concentration presence in blood. The protein's sensitivity is reduced when low concentration of glucose, thus reducing the risk of hypoglycemia. [2] In addition, it can effectively cover the risk of fluctuations of blood sugar levels.
The Hagedorn Prize is an annual award within the field of medical research, specifically recognizing outstanding contributions to diabetes research and endocrinology.Named after Hans Christian Hagedorn, a renowned Danish scientist and co-founder of Nordisk Insulinlaboratorium [1] (now part of Novo Nordisk), the prize celebrates achievements in the understanding and treatment of diabetes.
The AIDA software is intended to serve as an educational support tool and can be used by anyone — person with diabetes, relative of a patient, health care professional (doctor, nurse, clinical diabetes educator, dietician, pharmacist, etc.), or student — even if they may have minimal knowledge of the pathophysiology of diabetes mellitus.
Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity care.. The company develops a long line of blockbuster glucagon-like ...
An experimental oral form of a Novo Nordisk drug for type 2 diabetes posed no greater risk of serious heart problems or death than a placebo in patients at high risk for such complications ...
Novo Nordisk's Ozempic slowed the worsening of kidney dysfunction in patients with type 2 diabetes and lowered the risk of kidney failure, heart problems, stroke and death, according to detailed ...
Novo Nordisk created "aspart" and marketed it as NovoLog/NovoRapid (UK-CAN) as a rapid-acting insulin analogue. It was created through recombinant DNA technology so that the amino acid, B28, which is normally proline , is substituted with an aspartic acid residue.
Novo has another long-acting insulin, Tresiba, on the market. "Novo Nordisk will phase out, then permanently discontinue Levemir in the U.S. on December 31, 2024," the company said in a statement.